Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CEA Immunoscintigraphy & PET in Recurrent Colorectal Carcinoma
NCT00001568Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 1997
- Modality
- Antibody Fragments, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of arcitumomab and fludeoxyglucose f 18 in colorectal carcinoma (CRC) (2 cohorts), sponsored by National Cancer Institute. Primary endpoints: Sensitivity of FDG-PET and Anti-CEA Immunoscintigraphy, Specificity of FDG-PET and Anti-CEA Immunoscintigraphy and 2 more. Started Feb 1997; status: completed.
02
Drugs
arcitumomabfludeoxyglucose f 18
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT00001568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001568.